ERCC1 and gastric cancer: On the other hand, there was no relationship in this study between clinical outcome and the pharmacogenetic markers reported in earlier studies, such as TS, DPD, and ERCC1. This suggests that these markers might not correlate with chemosensitivity to the FP treatment in gastric cancer patients.